The retreat of corporate venture funding?
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
Radiotherapeutics remain in the deal-making frame
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
Better late than never for Boehringer in Covid-19
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Merck & Co makes the accelerated approval pathway its own
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.
